Ikarovec

About:

Ikarovek is working on early stage assets intended for the treatment of diabetic macular edama.

Top Investors: Future Planet Capital, LifeArc, Parkwalk Advisors, UK Innovation & Science Seed Fund, LifeArc Ventures

Description:

Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Total Funding Amount:

10.5M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Cambridgeshire, United Kingdom

Founded Date:

2018-01-01

Founders:

Peter Widdowson

Number of Employees:

1-10

Last Funding Date:

2024-10-23

IPO Status:

Private

Industries: